|
(ÁÖ)´ë¿õ¹ÙÀÌ¿À |
Á¦¾à»ç °³¹ßÆÀ PV ´ã´çÀÚ ½ÅÀÔ/°æ·Â ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.20 |
|
|
(ÁÖ)Å¥¶óƼ½º |
ÀÓ»óÀÎÇã°¡ÆÀ PV Á¤±ÔÁ÷ ¸ðÁý
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
06.22 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK global PS] SP / ERA / PL ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
12.02 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
07.02 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.07 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
04.23 |
|
|
ÈÞÁ©(ÁÖ) |
[ÀÇÇÐPVÆÀ] PV ½ÅÀÔ/°æ·Â
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
03.14 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV ÀÎÅÏ»ç¿ø ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
03.02 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
PV Specialist ¸ðÁý(½ÅÀÔÁö¿ø°¡´É/1³â°è¾à±Ù¹«)
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
02.16 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] PV Associate ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
01.29 |
|
|
(ÁÖ)¿¤¿¡½ºÄÉÀ̱۷ιúÆĸ¶¼ºñ½º |
[LSK Global PS] PS ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
01.11 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.18 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.12 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] Post Marketing Surveillance lead
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
5³â¡è |
ä¿ë½Ã |
05.08 |
|